Summary by Futu AI
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on May 24, 2024. The registration pertains to the resale of up to 6,217,723 shares of common stock by selling stockholders. These shares include 1,700,000 currently outstanding shares, shares issuable upon the exercise of various warrants acquired in a private placement transaction on May 17, 2024, and shares issuable upon the exercise of Wainwright Warrants. T2 Biosystems will not sell any shares or receive proceeds from the selling stockholders' sales, but will receive proceeds if the warrants are exercised for cash. The selling stockholders will cover all commissions and discounts from their sales, while T2 Biosystems will bear all other costs associated with the registration. The common stock is traded on The NASDAQ Capital Market under the symbol 'TTOO', with the last reported sale price being $5.16 per share as of May 23, 2024. The company cautions that investing in its common stock involves a high degree of risk.